The 48 linked references in paper К. Мukhin Yu., О. Pylaeva A., К. Мухин Ю., О. Пылаева Н. (2018) “Руфинамид (иновелон) в лечении синдрома Леннокса–Гасто (обзор литературы) // Rufinamide (inovelon) in the treatment of Lennox–gastaut syndrome (a review of literature)” / spz:neicon:rjdn:y:2018:i:2:p:20-33

  1. Al-Banji M.H., Zahr D.K., Jan M.M. Lennox–Gastaut syndrome. Management update. Neurosciences (Riyadh) 2015;20(3):207–12. PMID: 26166587. DOI: 10.17712/nsj.2015.3.20140677.
  2. Albini M., Morano A., Fanella M. et al. Effectiveness of rufinamide in the treatment of idiopathic generalized epilepsy with atypical evolution: case report and review of the literature. Clin EEG Neurosci 2016;47(2):162–6. DOI: 10.1177/1550059414559940.
  3. Aldenkamp A., Besag F., Gobbi G. et al. Psychiatric and behavioural disorders in children with epilepsy (ILAE Task Force report): adverse cognitive and behavioral effects of antiepileptic drugs in children. Epileptic Disord 2016. PMID: 27184878. DOI: 10.1684/epd.2016.0817.
  4. Alsaad A.M., Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol 2014;78(6):1264–71. PMID: 25132372. DOI: 10.1111/ bcp.12479.
  5. Brodie M.J., Rosenfeld W.E., Vazquez B. et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50(8):1899–909. PMID: 19490053. DOI: 10.1111/j.1528-1167.2009.02160.x.
  6. Cheng-Hakimian A., Anderson G.D., Miller J.W. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006;60(11):1497–501. PMID: 17073844. DOI: 10.1111/j.1742-1241.2006.01173.x.
  7. Conry J.A., Ng Y.T., Paolicchi J.M. et al. Clobazam in the treatment of Lennox– Gastaut syndrome. Epilepsia 2009;50(5):1158–66. PMID: 19170737. DOI: 10.1111/j.1528-1167.2008.01935.x.
  8. Coppola G., Besag F., Cusmai R. et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol 2014;18(6):685–90. DOI: 10.1016/j. ejpn.2014.05.008.
  9. Coppola G., Grosso S., Franzoni E. et al. Rufinamide in children and adults with Lennox–Gastaut syndrome: first Italian multicenter experience. Seizure 2010;19(9):587–91. DOI: 10.1016/j.seizure.2010.09.008.
  10. Coppola G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat 2011;7:399–407. PMID: 21792306. DOI: 10.2147/NDT.S13910.
  11. Cross J.H., Auvin S., Falip M. et al. Expert opinion on the management of Lennox– Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol 2017;8:505. PMID: 29085326. DOI: 10.3389/fneur.2017.00505.
  12. Dodson W.E. Felbamate in the treatment of Lennox–Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993;34(Suppl 7):S18–24. DOI: 10.1111/j.1528-1157.1993.tb04590.x.
  13. Glauser T., Kluger G., Sachdeo R. et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70(21):1950–8. DOI: 10.1212/01.wnl.0000303813.95800.0d.
  14. Glauser T.A., Levisohn P.M., Ritter F., Sachdeo R.C. Topiramate in Lennox– Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000;41(Suppl 1):S86–90. DOI: 10.1111/j.1528-1157.2000.tb01563.x.
  15. Hakimian S., Cheng-Hakimian A., Anderson G.D., Miller J.W. Rufinamide: a new antiepileptic medication. Expert Opin Pharmacother 2007;8(12):1931–40. PMID: 17696794. DOI: 10.1517/14656566.8.12.1931.
  16. Hancock E.C., Cross J.H. Treatment of Lennox–Gastaut syndrome. Cochrane Database Syst Rev 2013;2:CD003277. DOI: 10.1002/14651858.CD003277.
  17. Jaraba S., Santamarina E., Miró J. et al. Rufinamide in children and adults in routine clinical practice. Acta Neurol Scand 2017;135(1):122–8. DOI: 10.1111/ane.12572.
  18. Kerr M., Kluger G., Philip S. Evolution and management of Lennox–Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord 2011;13(Suppl 1):S15– S26. PMID: 21669559. DOI: 10.1684/ epd.2011.0409.
  19. Kessler S.K., McCarthy A., Cnaan A., Dlugos D.J. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox–Gastaut Syndrome. Epilepsy Res 2015;112:18–26. PMID: 25847334. DOI: 10.1016/j.eplepsyres.2015.02.003.
  20. Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res 2012;2(2):33–7. PMID: 24649460. DOI: 10.14581/jer.12009.
  21. Kim S.H., Lee J.H., Ryu H.W. et al. Shortterm efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy. Epileptic Disord 2013;15(1):49–54. PMID: 23531645. DOI: 10.1684/epd.2013.0557.
  22. Kluger G., Haberlandt E., Kurlemann G. et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010;17(4):546–8. PMID: 20185372. DOI: 10.1016/j.yebeh.2010.01.005.
  23. Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010 Sep;122(3):202–8. PMID: 20199521. DOI: 10.1111/j.1600-0404.2010.01334.x.
  24. Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in children and young adults with Lennox–Gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg 2013;115(7): 926–9. PMID: 23083943. DOI: 10.1016/j. clineuro.2012.09.021.
  25. Liao W.P., Shi Y.W., Long Y.S. et al. Partial epilepsy with antecedent febrile seizures and seizure aggravation by antiepileptic drugs: associated with loss of function of Na(v) 1.1. Epilepsia 2010;51(9):1669–78. PMID: 20550552. DOI: 10.1111/j.1528-1167.2010.02645.x.
  26. McMurray R., Striano P. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/ tolerability of rufinamide. Neurol Ther 2016;5(1):35–43. PMID: 26861566. DOI: 10.1007/s40120-016-0041-9.
  27. Moavero R., Santarone M.E., Galasso C., Curatolo P. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev 2017;39(6):464–9. PMID: 28202262. DOI: 10.1016/j.braindev.2017.01.006.
  28. Montouris G.D., Wheless J.W., Glauser T.A. The efficacy and tolerability of pharmacologic treatment options for Lennox– Gastaut syndrome. Epilepsia 2014; 55(Suppl 4):10–20. PMID: 25284033. DOI: 10.1111/epi.12732.
  29. Motte J., Trevathan E., Arvidsson J.F. et al. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. N Engl J Med 1997;337(25):1807–12. DOI: 10.1056/NEJM199712183372504.
  30. Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8. PMID: 22780580. DOI: 10.1111/j.1528-1167.2012.03579.x.
  31. Ng Y.T., Conry J.A., Drummond R. et al. Randomized, phase III study results of clobazam in Lennox–Gastaut syndrome. Neurology 2011;77(15):1473–81. PMID: 21956725. DOI: 10.1212/ WNL.0b013e318232de76.
  32. Nikanorova M., Brandt C., Auvin S., McMurray R. Real-world data on rufinamide treatment in patients with Lennox– Gastaut syndrome: results from a European noninterventional registry study. Epilepsy Behav 2017;76:63–70. PMID: 28927712. DOI: 10.1016/j.yebeh.2017.08.026.
  33. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial. Epilepsy Res 2016;121:1–7. PMID: 26827266. DOI: 10.1016/j. eplepsyres.2016.01.002.
  34. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res 2014;108(9): 1627–36. PMID: 25219353. DOI: 10.1016/j.eplepsyres.2014.08.019.
  35. Ostendorf A.P., Ng Y.T. Treatment-resistant Lennox–Gastaut syndrome: therapeutic trends, challenges and future directions. Neuropsychiatr Dis Treat 2017;13:1131– 40. PMID: 28461749. DOI: 10.2147/NDT. S115996.
  36. Resnick T., Arzimanoglou A., Brown L.W. et al. Rufinamide from clinical trials to clinical practice in the United States and Europe. Epileptic Disord 2011;13(Suppl 1):S27–43. PMID: 21669560. DOI: 10.1684/epd.2011.0421.
  37. Sachdeo R.C., Glauser T.A., Ritter F. et al. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology 1999;52(9):1882–7. DOI: 10.1212/ WNL.52.9.1882.
  38. Schimpf R., Veltmann C., Papavassiliu T. et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm 2012;9(5):776– 81. PMID: 22245794. DOI: 10.1016/j. hrthm.2012.01.006.
  39. The Felbamate Study Group in Lennox– Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). N Engl J Med 1993;328(1):29–33. DOI: 10.1056/ NEJM199301073280105.
  40. Thome-Souza S., Kadish N.E., Ramgopal S. et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia 2014;55(8):1235–44. PMID: 25070475. DOI: 10.1111/epi.12689.
  41. Tomson T., Marson A., Boon P. et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015;56(7):1006–19. DOI: 10.1111/epi.13021.
  42. Vendrame M., Loddenkemper T., Gooty V.D. et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol 2010;43(3):155–8. PMID: 20691934. DOI: 10.1016/j.pediatrneurol.2010.04.003.
  43. Verrotti A., Loiacono G., Ballone E. et al. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol 2011;44(5):347–9. PMID: 21481742. DOI: 10.1016/j.pediatrneurol.2010.12.005.
  44. Verrotti A., Loiacono G., Rossi A. et al. Successful treatment of refractory seizures with rufinamide in children with schizencephaly: report of 3 cases. J Child Neurol 2015;30(8):1079–83. DOI: 10.1177/0883073814542951.
  45. Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9(4):353–412. PMID: 18077226. DOI: 10.1684/epd.2007.0144.
  46. Wheless J.W., Clarke D.F., Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(suppl 1):S1–56. PMID: 16615562. DOI: 10.1177/088307380502000101.
  47. Wheless J.W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009;24(12):1520–5. PMID: 19955344. DOI: 10.1177/0883073809350508.
  48. Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox–Gastaut syndrome: a comprehensive overview. Paediatric Drugs 2011;13(2):97–106. PMID: 21351809. DOI: 10.2165/11586920-000000000-00000.